These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34013757)

  • 41. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study.
    Sintnicolaas K; van Marwijk Kooij M; van Prooijen HC; van Dijk BA; van Putten WL; Claas FH; Novotny VM; Brand A
    Blood; 1995 Feb; 85(3):824-8. PubMed ID: 7833483
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of efficacy of low and high dose prophylactic platelet transfusion therapy in thrombocytopenic haemato-oncology patients.
    Dhiman Y; Hans R; Sharma RR; Malhotra P; Marwaha N
    Transfus Apher Sci; 2020 Feb; 59(1):102610. PubMed ID: 31345687
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer.
    Goldberg GL; Gibbon DG; Smith HO; DeVictoria C; Runowicz CD; Burns ER
    J Clin Oncol; 1994 Nov; 12(11):2317-20. PubMed ID: 7964946
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alloimmune refractoriness to platelet transfusions.
    Sandler SG
    Curr Opin Hematol; 1997 Nov; 4(6):470-3. PubMed ID: 9359008
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and quality evaluation of apheresis vs random-donor platelet concentrates stored for 7 days.
    Hussein E
    Transfus Med; 2015 Feb; 25(1):20-6. PubMed ID: 25808050
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Guidelines for platelet transfusions. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force.
    Murphy MF; Brozovic B; Murphy W; Ouwehand W; Waters AH
    Transfus Med; 1992 Dec; 2(4):311-8. PubMed ID: 1339584
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Anti-CD36 Mediated Platelet Transfusion Refractoriness and Related Cases After Stem Cell Transplantation].
    Zhou Y; Li LL; Zhong ZL; Liu XJ; Liu JL; Shen WD; Wu GG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):541-546. PubMed ID: 29665929
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Complement as an Immune Barrier in Platelet Transfusion Refractoriness.
    Meinke S; Karlström C; Höglund P
    Transfus Med Rev; 2019 Oct; 33(4):231-235. PubMed ID: 31679761
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravascular and total body platelet equilibrium in healthy volunteers and in thrombocytopenic patients transfused with single donor platelets.
    Brubaker DB; Marcus C; Holmes E
    Am J Hematol; 1998 Jul; 58(3):165-76. PubMed ID: 9662266
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunological platelet transfusion refractoriness: current insights from mechanisms to therapeutics.
    Chen X; Zhao Y; Lv Y; Xie J
    Platelets; 2024 Dec; 35(1):2306983. PubMed ID: 38314765
    [TBL] [Abstract][Full Text] [Related]  

  • 51. One-unit compared to two-unit platelet transfusions for adult oncology outpatients.
    Gehrie EA; Frank SM; Visagie M; Grabowski MK; Tobian AAR; Strockbine VL; DeMario VM; Lawrence CE; Hambley BC; Uglik K; Ness PM; DeZern AE; Bloch EM
    Vox Sang; 2019 Jul; 114(5):517-522. PubMed ID: 31056742
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients.
    Vo P; Purev E; West KA; McDuffee E; Worthy T; Cook L; Hawks G; Wells B; Shalabi R; Flegel WA; Adams SD; Reger R; Aue G; Tian X; Childs R
    Br J Haematol; 2020 May; 189(3):551-558. PubMed ID: 32086819
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial.
    Lee EJ; Schiffer CA
    Transfusion; 1989 Jun; 29(5):384-9. PubMed ID: 2660333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Analysis of transfusion effect of different platelet matching schemes in patients with platelet transfusion refractoriness].
    Liang YJ; Wang H; Zhao PZ; Wang F; Li Q; Xu Y; Wu YX; Zhang DM; He XH
    Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(11):865-869. PubMed ID: 38462363
    [No Abstract]   [Full Text] [Related]  

  • 55. Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations.
    Daly PA; Schiffer CA; Aisner J; Wiernik PH
    JAMA; 1980 Feb; 243(5):435-8. PubMed ID: 7351763
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Platelet transfusions: treatment options for hemorrhage secondary to thrombocytopenia.
    Hux BD; Martin LG
    J Vet Emerg Crit Care (San Antonio); 2012 Feb; 22(1):73-80. PubMed ID: 23016744
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and laboratory factors underlying refractoriness to platelet transfusions.
    Friedberg RC
    J Clin Apher; 1996; 11(3):143-8. PubMed ID: 8915819
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Febrile reactions after platelet transfusion: the effect of single versus multiple donors.
    Chambers LA; Kruskall MS; Pacini DG; Donovan LM
    Transfusion; 1990; 30(3):219-21. PubMed ID: 1967118
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selection of histocompatible apheresis platelet donors by cross-matching random donor platelet concentrates.
    O'Connell BA; Lee EJ; Rothko K; Hussein MA; Schiffer CA
    Blood; 1992 Jan; 79(2):527-31. PubMed ID: 1730095
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The definition of refractoriness to platelet transfusions.
    Bishop JF; Matthews JP; Yuen K; McGrath K; Wolf MM; Szer J
    Transfus Med; 1992 Mar; 2(1):35-41. PubMed ID: 1308461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.